Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX – Get Free Report) was the recipient of a significant growth in short interest during the month of September. As of September 30th, there was short interest totalling 371,600 shares, a growth of 6.0% from the September 15th total of 350,500 shares. Based on an average daily trading volume, of 214,600 shares, the short-interest ratio is currently 1.7 days. Approximately 2.9% of the company’s stock are short sold.
Analyst Ratings Changes
Separately, StockNews.com began coverage on Eagle Pharmaceuticals in a report on Saturday, October 12th. They issued a “hold” rating on the stock.
Check Out Our Latest Stock Analysis on Eagle Pharmaceuticals
Eagle Pharmaceuticals Stock Performance
Hedge Funds Weigh In On Eagle Pharmaceuticals
Hedge funds have recently added to or reduced their stakes in the company. Headlands Technologies LLC increased its holdings in Eagle Pharmaceuticals by 75.7% in the first quarter. Headlands Technologies LLC now owns 6,641 shares of the specialty pharmaceutical company’s stock worth $35,000 after buying an additional 2,861 shares during the last quarter. Creative Planning acquired a new position in Eagle Pharmaceuticals in the third quarter worth approximately $59,000. Mackenzie Financial Corp acquired a new position in Eagle Pharmaceuticals in the second quarter worth approximately $60,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in Eagle Pharmaceuticals during the second quarter valued at approximately $65,000. Finally, Fidelis Capital Partners LLC acquired a new position in Eagle Pharmaceuticals during the second quarter valued at approximately $71,000. Institutional investors and hedge funds own 85.36% of the company’s stock.
About Eagle Pharmaceuticals
Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.
See Also
- Five stocks we like better than Eagle Pharmaceuticals
- NYSE Stocks Give Investors a Variety of Quality OptionsÂ
- Oil Prices Fall, Sector Pulls Back: Time to Buy this Stock?
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- AI Boom Fuels Demand for Dominion Energy Stock
- Basic Materials Stocks Investing
- Cathie Wood Cuts Robinhood Holdings—Follow Her Lead or Stay Put?
Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.